
ALT "Research supported through RadNet Manchester will allow us to understand better the complexities that influence an individual patient’s response to radiotherapy and how we can use this to define more personalised, effective treatment with fewer side effects. Personalised therapy is dependent on identifying the biological indicators of treatment success or failure, whilst understanding also how patient specific factors such as pre-existing medical conditions, influence response. Our unique and inclusive programme of research aims to bridge these two themes to ensure better outcomes for all." Prof. Kaye Williams Deputy Director of RadNet Manchester

ALT "Securing funding for our research into virtual clinical trials marks a significant step forward for radiotherapy research. We are hopeful that these simulations, such as digital twins to model patients’ outcome, will make trials faster, safer, and more likely to benefit patients. By reducing the burden on patients and enhancing the efficiencies of traditional trials, virtual trials hold great promise for advancing personalised medicine and improving how advances in radiotherapy reach those who need them most." --- Prof. Corinne Faivre-Finn co-theme lead for Inclusive and personalised radiotherapy for complex patients

ALT Ferdi Schüth, Juryvorsitzender, Direktor am Max-Planck-Institut für Kohlenforschung ; Otmar D. Wiestler, Präsident der Helmholtz Gemeinschaft; Ellen Sletten (UCLA); Oliver Bruns (NCT/UCC und DKFZ) sowie Volker Meyer-Guckel, Generalsekretär des Stifterverbandes für die Deutsche Wissenschaft (from left to right) Photo: Helmholtz/Phil Dera



























